Keith Martin is Managing Director of the Centre for Eye Research Australia and Ringland Anderson Professor and Head of Ophthalmology at the University of Melbourne. Until January 2019, he was Head of Ophthalmology at the University of Cambridge, Deputy Director of the University’s John van Geest Centre for Brain Repair and an Affiliate Principal Investigator at the Wellcome Trust - MRC Cambridge Stem Cell Institute. He was also Academic Lead for Ophthalmology and Lead Clinician for Glaucoma at the Cambridge University Hospitals NHS Foundation Trust.

​

He graduated from the University of Cambridge with a 'Triple first' in Medical Sciences and Neuroscience before completing clinical Training at Oxford University Clinical School, Ophthalmology Residency in Cambridge and Clinical and Research Fellowships in Glaucoma at Moorfields Eye Hospital in London and the Wilmer Eye Institute in Baltimore.
Professor Martin is working to develop new treatments for eye disease using stem cells, gene therapy and other techniques. In 2010, Professor Martin won the ARVO Foundation for Eye Research Translational Research Award, an international prize to a researcher from any country under the age of 50 years whose research is judged to have the potential to lead to major breakthroughs in the treatment of eye disease. He was also a winner of the World Glaucoma Association Senior Clinician Scientist Award in 2011 and was awarded the Duke Elder Medal by the Royal College of Ophthalmologists in 2017.

​

He is co-founder of Quethera, a Cambridge-based gene therapy company which has developed a gene therapy for glaucoma that is currently progressing towards human clinical trials. His other current main research interest is in the potential for regeneration and repair of nerve damage in the eye and brain. Clinically, Professor Martin specialises in the medical and surgical management of complex glaucoma. He is currently President of the World Glaucoma Association, the largest glaucoma organisation in the world.